Evaluation of Prostatic Artery Embolization Efficiency in Benign Prostatic Hyperplasia Patients with High Comorbidity

Basit Öğe Kaydı
dc.authorwosidçelik, hüseyin/AAA-3033-2021
dc.authorwosidFırat, Ali/AHB-8427-2022
dc.authorwosidSaraç, Kaya/ABI-1091-2020
dc.authorwosidYıldırım, İsmail Okan/AFR-8243-2022
dc.contributor.authorYildirim, Ismail Okan
dc.contributor.authorDuman, Enes
dc.contributor.authorFirat, Ali
dc.contributor.authorCelik, Huseyin
dc.contributor.authorSarac, Kaya
dc.date.accessioned2024-08-04T20:10:30Z
dc.date.available2024-08-04T20:10:30Z
dc.date.issued2018
dc.departmentİnönü Üniversitesien_US
dc.description.abstractObjective: The purpose of this study was to evaluate efficacy outcomes following prostate artery embolization (PAE) for the treatment of benign prostatic hyperplasia (BPH) patients with high comorbidity. Materials and Methods: This retrospective study included 22 patients treated with PAE from May 2015 to June 2017. Patients with Charlson comorbidity index >= 2, International Prostate Symptom Score (IPSS) >12, prostate specific antigen (PSA) levels <4 ng/mL or between 4 and 10 ng/mL with negative prostate biopsy and total prostate volume (TPV) >90 cm(3) were included. Total PSA, maximum flow rate (Q(max)), TPV, IPSS, post-voiding residual (PVR) values were recorded in all patients in the urology clinic before PAE and at 3 and 6 months after PAE. Results: The average patient age was 73.86 +/- 6.25 years and operative time was 80 minutes (range, 60-120 min). Pre-PAE and 6-month post-PAE values were: IPSS: 25.18 +/- 6.75 an d 11.27 +/- 3.29 (p<0.05), Q(max): 8.31 +/- 3.12 and 17.22 +/- 3.23 (p<0.05), PVR: 87.9 +/- 19.25 and 25.86 +/- 7.72 (p<0.05), TPV: 134.45 +/- 57.56 and 86 +/- 15.4 (p<0.05), and PSA: 3.89 +/- 1.26 and 2.11 +/- 1.06 (p<0.05). Embolization was performed unilaterally due to atherosclerosis and strictures in the internal iliac artery branches in 2 patients. After the procedure, 2 patients experienced transient hematuria which did not require bladder irrigation, 1 patient had acute urinary retention due to dysuria, and 1 patient had transient hematospermia. Conclusion: PAE may be an alternative treatment method in BPH patients with high comorbidity.en_US
dc.identifier.doi10.4274/uob.937
dc.identifier.endpage17en_US
dc.identifier.issn2147-2270
dc.identifier.issue1en_US
dc.identifier.startpage14en_US
dc.identifier.trdizinid271852en_US
dc.identifier.urihttps://doi.org/10.4274/uob.937
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/271852
dc.identifier.urihttps://hdl.handle.net/11616/92807
dc.identifier.volume17en_US
dc.identifier.wosWOS:000429834600005en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.language.isoenen_US
dc.publisherGalenos Yayinciliken_US
dc.relation.ispartofUroonkoloji Bulteni-Bulletin of Urooncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectHigh comorbidityen_US
dc.subjectbenign prostatic hyperplasiaen_US
dc.subjectprostate artery embolizationen_US
dc.titleEvaluation of Prostatic Artery Embolization Efficiency in Benign Prostatic Hyperplasia Patients with High Comorbidityen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu